Instructor Notes — Chapter 13

Teaching notes

What this chapter is actually for

Two deliverables, and the second is the one that transfers furthest:

1. The redundancy argument. Appetite is a network defending a set point, which is why single-target drugs failed and why the successful ones hit several nodes at once. This is the best available answer to "what made GLP-1 different?"
2. The deficiency/disease distinction. Leptin works dramatically for leptin deficiency and does nothing for common obesity. Setmelanotide works for POMC deficiency and not for common obesity. A model of a deficiency is not a model of the common disease it resembles, and students who internalize this here will read Chapter 17's BPC-157 rodent models very differently.

The chapter also closes Part II, so it is a natural place to consolidate before the evidence thins.

Common misconceptions

"Leptin was a failure." It produced no general obesity drug and it produced the entire modern field — adipose tissue as an endocrine organ, the hypothalamic circuitry, the monogenic obesities, and setmelanotide. Students who leave calling it a failure have learned the wrong lesson about what research produces.

"Obesity is a hormone problem — they found the hormone." Extremely common, and the honest answer is more interesting than yes or no. Exercise 13.25 is the model response.

"Setmelanotide is an obesity drug." It is a drug for specified genetic deficiencies. The gap between "genetic obesity" and the approved indication is where inappropriate use would occur, and it is worth naming.

"CagriSema is basically tirzepatide." Two molecules versus one; tunable ratio versus fixed. Students consistently flatten this, and the distinction matters for how each is developed.

"The supplement claim is obviously nonsense." It is not obviously anything — fiber genuinely affects GLP-1 secretion. The ❌ attaches to the comparison, and a student who dismisses the whole category has made the Chapter 6 §6.5 error and would lose the argument to anyone who knows the physiology.

"Small trials are weak evidence." Usually. Case Study 2 argues the concern applies with much less force when the effect is dramatic and the mechanism confirmed. This is not an exception to Chapter 5 — it is a statement about when Chapter 5's concern bites, and students should be able to say which.

The hardest point to teach

That a proven mechanism does not generalize.

Students accept "plausible mechanism isn't evidence" by this point in the book. Setmelanotide breaks their model, because here the mechanism is demonstrated in humans by a successful trial — and it still does not extend to common obesity.

The move that works: ask what the demonstration was conditional on. It showed that MC4R agonism corrects a deficient melanocortin signal. In common obesity the signal is not deficient. The trial proved something true and narrow, and the narrowness is in the premise rather than in the result.

Then generalize: every mechanistic demonstration is conditional on the state of the system it was demonstrated in. That framing carries into Part III much better than "mechanism isn't proof."

Demonstrations that work

The parabiosis reasoning, before the reveal. Describe the two experiments — ob/ob joined to normal loses weight; db/db joined to normal starves the normal mouse — and ask the class what they infer. Students reliably get there, and having reconstructed a 1960s inference themselves makes leptin resistance memorable rather than a fact to recall.

Build the network diagram live. Ask for appetite signals; write each on the board with its tissue. When the list reaches ten or twelve, ask: "if I block one, what happens?" The redundancy argument arrives from the room rather than from you.

Two labels. Project setmelanotide's Indications section next to a GLP-1 agonist's. One names genetic conditions requiring molecular confirmation; the other names a BMI threshold. Ninety seconds, and the precision-medicine point lands harder than any explanation.

The supplement claim, dismantled in order. Put the four reasons on the board one at a time and ask after each whether the claim is dead yet. Students usually think it dies at ① or ②. Reason ④ — every human has had normal GLP-1 physiology their whole life — is the one that requires no measurement, and watching them realize that is the best moment in the chapter.

Timing

For a 75-minute session:

If short, compress §13.6 and §13.9. Do not cut the leptin material or §13.8.

Assessment notes

Discriminating items: 13.9, 13.16, 13.19, 13.22, 13.29.

13.16 (why a proven mechanism doesn't generalize) is the best single item and the hardest. Full credit requires identifying what the demonstration was conditional on, not merely restating that it doesn't extend.

13.29 (rank by what the field learned) rewards students who notice that the ranking is nearly the inverse of commercial success. That observation is the chapter's quiet argument about how to evaluate research.

13.31 (Field 8 for the whole dossier) — grade the "who makes each claim" line most carefully. It is where epistemic laundering becomes visible in the student's own entries.